Although legal in 28 states for medicinal use, cannabis is still considered a dangerous substance in much of the country. However, many experts now believe that cannabis is a safe alternative to pharmaceuticals for relieving symptoms related to multiple illnesses.
India Globalization Capital, Inc. (NYSE MKT: IGC) is developing disruptive new pharmaceutical therapies to fight a variety of ailments.
The cannabis industry has swiftly turned into a multi-billion dollar opportunity. In the United States, this market’s massive growth potential is being recognized as new states legalize marijuana for medical or recreational use.
Various public companies are accomplishing the two-fold mission of improving the health of our four-footed friends while giving investors the opportunity to capitalize on a multibillion-dollar industry.
Combination therapies that use cannabis-based pain reduction methods without the negative side effects of opioids are looking to be a positive growth opportunity among specialty pharmaceuticals, particularly for postoperative and chronic pain relief.
How does a company in the mining industry successfully move toward becoming a leader in the marijuana sector, specifically cannabinoid-based pharmaceutical therapies that treat a variety of diseases and conditions?
India Globalization Capital (NYSE MKT: IGC) formerly mined and converted low-grade iron ore to high-grade ore until prices plummeted. It was then that company management made the decision that to preserve shareholder value it must change course.
Savvy investors should be keeping a close eye on some key developments that have taken place within the past year relating to Alzheimer’s disease, medical cannabis, and India Globalization Capital (NYSE MKT: IGC)
Cannabis is now legal medically or recreationally in 28 states in the U.S., and companies such as India Globalization Capital, Inc. (NYSE MKT: IGC) are developing revolutionary cannabinoid-based combination pharmaceutical therapies.
InMed Pharmaceuticals, Inc.’s (CSE: IN) (OTCQB: IMLFF) study, which generated an article published in the European Journal of Pain (http://nnw.fm/SVF1j), sets the stage for more research into how a topically-applied drug can provide relief of chronic or acute pain without central side effects, according to Dr. Sazzad Hossain, chief scientific officer of InMed.
Although the marijuana industry is comprised of some incredible companies, investors must be selective and focus on the real players.
Looking to gain an advantageous foothold in the burgeoning medical marijuana market, India Globalization Capital, Inc. (NYSE MKT: IGC) is developing innovative cannabis-based combination therapies that have application for both humans and animals.
India Globalization Capital, Inc. (NYSE MKT: IGC) is a first mover in developing a portfolio of products using cannabis-based “combination therapies” for the treatment of pain and other conditions.
The fastest-growing industry with the most consistent growth rate in North America is legal marijuana. A recent Forbes article says that the market could grow 700% by 2020.
At first blush, India Globalization Capital (NYSE: IGC) would seem a curiosity clothed in an enigma. Just how does a NYSE company move from a successful mining orientation to a pioneer in the development of multiple cannabinoid-based pharmaceutical therapies to treat pain and disease?
